Drug maker Boehringer Ingelheim has announced it has initiated a pivotal global, open-label randomized phase III clinical trial to evaluate the efficacy of its targeted oral drug afatinib in patients with advanced, metastatic HER2 positive breast cancer who have undergone prior treatment with trastuzumab.
The question the trial will resolve is whether afatinib + vinorelbine extends the lives of these patients longer than trastuzumab + vinorelbine. Thus the primary endpoint in the "LUX-Breast 1" trial, as it will be called, will be progression-free survival (PFS). Secondary endpoints include overall survival (OS), safety and tolerability.
"LUX-Breast 1" joins " LUX -Lung 1", another clinical trial sponsored by Boehringer Ingelheim that is investigating the efficacy of afatinib in select patients with lung cancer.
CANCER TYPE(S)
HER2-positive breast cancer
TREATMENT TYPE(S)
Targeted therapy. Afatinib is believed to inhibit A) the epidermal growth factor receptor (EGFR/HER1) and B) the human epidermal receptor HER2.
Source
Medical News Today
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
